Table 1.
Clinical, laboratory, MRI, and biopsy results at inclusion
| Baseline characteristics | Values |
|---|---|
| Age (yr) | 64 (60–69) |
| Family history of PCa | 142/713 (19.9) |
| PSA (ng/ml) | 6.79 (5.30–9.80) |
| Prostate volume (ml) | 43 (33–56) |
| PSA density (ng/ml/ml) | 0.16 (0.12–0.25) |
| cT stage | |
| Tx | 2/713 (0.3) |
| T1c | 450/713 (63.1) |
| T2a | 210/713 (29.5) |
| T2b | 21/713 (2.9) |
| T2c | 21/713 (2.9) |
| T3/T4 | 9/713 (1.3) |
| EAU risk group | |
| Low | 176/713 (24.7) |
| Intermediate | 430/713 (60.3) |
| High | 107/713 (15.0) |
| Number of lesions on MRI | |
| 0 | 73/713 (10.2) |
| 1 | 493/713 (69.1) |
| ≥2 | 147/713 (20.6) |
| MRI lesion site | |
| MRI index lesion | |
| PZ vs TZ/AFMS | 510/639 (79.8) vs 129/639 (20.2) |
| Posterior vs anterior | 448/637 (70.3) vs 189/637 (29.7) |
| MRI secondary lesion | |
| PZ vs TZ/AFMS | 104/147 (70.7) vs 43/147 (29.3) |
| Posterior vs anterior | 81/146 (55.5) vs 65 /146 (44.5) |
| Diameter on MRI (mm) | 13 (8–17) |
| Gleason grade group on biopsy | |
| GG1 | 217/713 (30.4) |
| GG2 | 292/713 (41.0) |
| GG3 | 154/713 (21.2) |
| GG4 | 34/713 (4.8) |
| GG5 | 16/713 (2.2) |
| Percentage of Gleason grade 4 or 5 | |
| 0 | 217/713 (30.4) |
| 1–9 | 79/713 (11) |
| 10 | 74/713 (10.4) |
| 20 | 48/713 (6.7) |
| 30 | 42/713 (5.9) |
| 40 | 49/713 (6.9) |
| 75 | 154/713 (21.6) |
| 100 | 50/713 (7.0) |
| MCCL (mm) | 7 (4–9) |
| Volume of grade 4 or 5 (ml) | 0.09 (0.00–0.67) |
| MCCL of grade 4 or 5 (mm) | 0.80 (0.00–3.81) |
AFMS = anterior fibromuscular stroma; EAU = European Association of Urology; GG = grade group; MCCL = maximum cancer core length; MRI = magnetic resonance imaging; PCa = prostate cancer; PSA = prostate-specific antigen; PZ = peripheral zone; TZ = transition zone.
Data are presented as n/N (%) or median (interquartile range).